STOCK TITAN

Regenerative Medical delays September quarterly report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Regenerative Medical Technology Group Inc. (RMTG) said it could not timely compile all information for the financial statements and related disclosures required in its Form 10-Q for the quarter ended September 30, 2026, without unreasonable effort or expense.

Filing Explained

RMTG's Form 10-Q for the quarter ended September 30, 2026 remains unfiled; the company expects to submit it within the five-day Rule 12b-25 grace period, making this notice a filing-timetable update rather than the quarter's financial report.

Grace period 5 calendar days Expected filing of the Form 10-Q following its prescribed due date
Rule 12b-25 regulatory
"five-day grace period provided by Rule 12b-25"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does RMTG expect to file its September 2026 quarterly report?

RMTG expects to file its Form 10-Q for the quarter ended September 30, 2026, on or before the end of the five-day grace period under Rule 12b-25. The company attributed the delay to its inability to compile the required financial-statement and related-disclosure information without unreasonable effort or expense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

    SEC FILE NUMBER
    000-56010
  NOTIFICATION OF LATE FILING    

 

(Check One): ☐ Form 10-K  ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
  ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR    

 

  For Period Ended: September 30, 2026
     
  ☐ Transition Report on Form 10-K
  ☐ Transition Report on Form 20-F
  ☐ Transition Report on Form 11-K
  ☐ Transition Report on Form 10-Q
  ☐ Transition Report on Form N-SAR
     
  For the Transition Period Ended: ___________________

     

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

 

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I - REGISTRANT INFORMATION

 

Full Name of Registrant: Regenerative Medical Technology Group Inc.
Former Name if Applicable: n/a
Address of Principal Executive Offices (Street and Number):

433 Plaza Real Suite 275

Boca Raton, Florida 33432

 

 

PART II - RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

 

  (a)  The reasons described in reasonable detail in Part III of this form could not be eliminated without  unreasonable effort or expense;
     
☒ (b)  The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

 

 

PART III - NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. The Registrant expects to file the Quarterly Report on or before the five-day grace period provided by Rule 12b-25.

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

David Christensen    (800)   956-3935
Name   Area Code    Telephone Number

                                                 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
   
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes      ☒ No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

   

2

 

Regenerative Medical Technology Group Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 16, 2026 By: /s/ David Christensen
   

Name: David Christensen

Title: President, Chief Executive Officer,

Chief Financial Officer, Secretary and Director

(Principal Executive Officer) (Principal Financial Officer) (Principal Accounting Officer)

 

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION

 

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

 

3

 

Keep reading